Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation

Pediatrics

Volumn 116, Issue 6, 2005, Pages 1361-1366

  Sperandio, Markus ^a   Beedgen, Bernd ^a   Feneberg, Reinhard ^a   Huppertz, Christina ^a   Brüssau, Jürgen ^a   Pöschl, Johannes ^a   Linderkamp, Otwin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Indomethacin; Patent ductus; Premature infants

Indexed keywords

FUROSEMIDE; GLUCOCORTICOID; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTERY SURGERY; ARTICLE; BRAIN HEMORRHAGE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; ENCEPHALOMALACIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GESTATIONAL AGE; HUMAN; HYPOXEMIA; INFANT; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NECROTIZING ENTEROCOLITIS; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY DISTRESS SYNDROME; SINGLE DRUG DOSE; STOMACH PERFORATION; THROMBOCYTOPENIA; URINE VOLUME; NEWBORN; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DUCTUS ARTERIOSUS, PATENT; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33644693335     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-0293     Document Type: Article

References (20)

1. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med. 1976;295:526-529
2. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976;295:530-533
3. Hammerman C. Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol. 1995;22:457-479
4. Itabashi K, Ohno T, Nishida H. Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr. 2003;143:203-207
5. Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2004;(1):CD003480
6. Rhodes PG, Ferguson MG, Reddy NS, Joransen JA, Gibson J. Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. Eur J Pediatr. 1988;147:481-484
7. Rennie JM, Cooke RW. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch Dis Child. 1991;66(Spec No):55-58
8. Tammela O, Ojala R, Iivainen T, et al. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr. 1999;134:552-557
9. Lee J, Rajadurai VS, Tan KW, Wong KY, Wong EH, Leong JY. Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. Pediatrics. 2003;112:345-350
10. Seyberth HW, Knapp G, Wolf D, Ulmer HE. Introduction of plasma indomethacin level monitoring and evaluation of an effective threshol level in very low birth weight infants with symptomatic patent ductus arteriosus. Eur J Pediatr. 1983;141:71-76
11. Schuster V, von Stockhausen HB, Seyberth HW. Effects of highly overdosed indomethacin in a preterm infant with symptomatic patent ductus arteriosus. Eur J Pediatr. 1990;149:651-653
12. Narayanan M, Schlueter M, Clyman RI. Incidence and outcome of a 10-fold indomethacin overdose in premature infants. J Pediatr. 1999;135:105-107
13. Bellander M, Ley D, Polberger S, Hellstrom-Westas L. Tolerance to early human milk feeding is not compromised by indomethacin in preterm infants with persistent ductus arteriosus. Acta Paediatr. 2003;92:1074-1078
14. Papile L-A, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500g. J Pediatr. 1978;92:529-534
15. Walsh M, Kliegman R. NEC: treatment based on staging criteria. Pediatr Clin North Am. 1986;33:179-199
16. Fujii AM, Brown E, Mirochnick M, O'Brien S, Kaufman G. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol. 2002;22:535-540
17. Jackson JK, Abdel-Rahman SM, Reavey D, Leeks S, Garg U, Hall RT. Use of indomethacin serum concentration in predicting effectiveness of dosing for symptomatic patent ductus arteriosus [abstract]. Hot Topics in Neonatology. Washington DC; 2000:352
18. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000;343:674-681
19. Ahlfors CE. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr. 2004;144:386-388
20. Gournay V, Savagner C, Thiriez G, Kuster A, Roze JC. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet. 2002;359:1486-1488